The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Alpha-cinnamide compositions for cancer.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Alpha-cinnamide compositions for cancer is a key innovation area in immuno-oncology
Alpha-cinnamide-based compounds are largely modulators of epigenetic proteins such as histone deacetylases (HDACs). HDACs are enzymes that regulate epigenetics by the removal of acetyl groups from the lysine residues of proteins, such as histones. Histone deacetylases have been variously implicated in different disease settings, including cancer, neurodegeneration and inflammation, as well as autoimmune, infectious, metabolic, haematologic, and cardiovascular disorders. Broad-spectrum HDAC inhibitors have been approved for the treatment of cancer. The potential for HDAC inhibitors as treatment for non-oncology indications has been recognised, but, is yet to be approved.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of alpha-cinnamide compositions for cancer.
Key players in alpha-cinnamide compositions for cancer – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to alpha-cinnamide compositions for cancer
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Bristol-Myers Squibb||290||Unlock company profile|
|Vertex Pharmaceuticals||191||Unlock company profile|
|Gilead Sciences||145||Unlock company profile|
|Nippon Shinyaku||95||Unlock company profile|
|Pfizer||85||Unlock company profile|
|Karyopharm Therapeutics||68||Unlock company profile|
|Agios Pharmaceuticals||64||Unlock company profile|
|F. Hoffmann-La Roche||45||Unlock company profile|
|E. Merck||45||Unlock company profile|
|Wellstat Management Company||39||Unlock company profile|
|Biogen||39||Unlock company profile|
|Alembic Pharmaceuticals||38||Unlock company profile|
|Oryzon Genomics||35||Unlock company profile|
|AbbVie||34||Unlock company profile|
|Incyte||28||Unlock company profile|
|Takeda Pharmaceutical||27||Unlock company profile|
|Mallinckrodt||24||Unlock company profile|
|Revolution Medicines||23||Unlock company profile|
|Karolinska Development||23||Unlock company profile|
|ESSA Pharma||20||Unlock company profile|
|Bayer||20||Unlock company profile|
|Pulmokine||18||Unlock company profile|
|Galderma Research and Development||18||Unlock company profile|
|Jacobio Pharmaceuticals Group||17||Unlock company profile|
|Madrigal Pharmaceuticals||17||Unlock company profile|
|Active Biotech||17||Unlock company profile|
|Mitsubishi Chemical Group||17||Unlock company profile|
|Otsuka Holdings||17||Unlock company profile|
|Sanofi||16||Unlock company profile|
|Abbott Laboratories||14||Unlock company profile|
|Karus Therapeutics||14||Unlock company profile|
|Eli Lilly and||14||Unlock company profile|
|Imago BioSciences||13||Unlock company profile|
|Immunomet Therapeutics||13||Unlock company profile|
|Kirin Holdings||13||Unlock company profile|
|Alphabet||12||Unlock company profile|
|Cancer Research Technology||12||Unlock company profile|
|Nuvation Bio||11||Unlock company profile|
|MSD||11||Unlock company profile|
|Johnson & Johnson||10||Unlock company profile|
|Macrophage Pharma||10||Unlock company profile|
|Jiangsu Haosen Pharmaceutical Group||9||Unlock company profile|
|Fujian Haixi Pharmaceuticals||9||Unlock company profile|
|Perrigo||9||Unlock company profile|
|Shanghai Hansoh Biomedical||8||Unlock company profile|
|Merck & Co||8||Unlock company profile|
|Chroma Therapeutics||8||Unlock company profile|
|Sentinel Oncology||7||Unlock company profile|
|U.S. Department of Veterans Affairs||7||Unlock company profile|
|Basilea Pharmaceutica||7||Unlock company profile|
Source: GlobalData Patent Analytics
Gilead Sciences is one of the key filers of patents in the alpha-cinnamide segment. It is engaged in the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, haematological, respiratory inflammatory, and liver diseases, as well as cancer and human immunodeficiency virus (HIV) infection. In 2015, Gilead Sciences acquired EpiTherapeutics gaining a footprint in the area of epigenetic research and development.
In terms of application diversity, Otsuka Holdings is the top company, followed by Wellstat Management Company and Bayer. By geographic reach, Revolution Medicines holds the top position. Jacobio Pharmaceuticals Group and Mitsubishi Chemical Group are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.